Larimar Therapeutics Inc.

LRMR | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.83

+$0.04 (+1.06%)

At close: Sep 21, 2026, 4:00 PM ET

$3.83

$0 (0.00%)

Pre-market: Sep 22, 2026, 7:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Key Executives

Name	Position
Carole S. Ben-Maimon	Chief Executive Officer, President & Director
Michael Celano	Secretary & Chief Financial Officer
Francis Michael Conway	Vice President & Controller
Gopi Shankar	Chief Development Officer
Jennifer Spokes Johansson	Vice President of Legal & Compliance
John Berman	Vice President of Finance & Administration
Russell G. Clayton	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 04, 2026	10-Q	Quarterly Report
Aug 04, 2026	8-K	Current Report
Jul 08, 2026	4	Filing
Jun 29, 2026	8-K	Current Report
May 20, 2026	4	Filing
May 20, 2026	4	Filing
May 20, 2026	4	Filing
May 20, 2026	4	Filing
May 20, 2026	4	Filing
May 20, 2026	4	Filing

View All SEC Filings ➞

Larimar Therapeutics Inc.

Country	United States
IPO Date	Jun 18, 2014
Industry	Biotechnology
Sector	Healthcare
Employees	71
CEO	Carole S. Ben-Maimon

Contact Details

Three Bala Plaza East Bala Cynwyd, Pennsylvania 19004 United States

https://www.larimartx.com

844 511 9056

Stock Details

Ticker Symbol	LRMR
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001374690
CUSIP Number	517125100
ISIN Number	US5171251003
SIC Code	2834